Infectious disease therapeutics market is anticipated to grow at a CAGR of 7.8% during the forecast period (2023-2030). Pivotal factors attributed to market growth including the increasing prevalence of infectious diseases across both developed and emerging economies and growing initiatives for spreading awareness about treatments and diagnosis have considerably propelled the growth of the infectious disease therapeutics market. The requirement for diagnosing and treatment created the demand for infectious disease therapeutics. According to the World Health Organization (WHO), an estimated 39.0 million people were living with HIV, in 2022. Around 1.3 million people were HIV positive in 2022, however, since 2010, the number of people acquiring HIV has been reduced by 38.0%. 

New HIV Infections (Per 1,000 Uninfected Population), By Region, 2022

Source: World Health Organization (WHO)

Furthermore, an estimated 10.6 million people fell ill with TB in 2021, an increase of 4.5% from 10.1 million in 2020. The TB incidence rate (new cases per 100,000 population per year) rose by 3.6% between 2020 and 2021, reversing declines of about 2% per year for most of the previous 2 decades. The net reduction from 2015 to 2021 was 10%, only halfway to the first milestone of the End TB Strategy.

Segmental Outlook 

The global infectious disease therapeutics market is segmented on the disease type, and end user. Based on the disease type, the market is sub-segmented into HIV, tuberculosis (TB), influenza, hepatitis, HPV, and malaria. Further, based on end users, the market is sub-segmented into hospitals, cosmetic and aesthetic clinics, and others.  Among the disease types, the influenza sub-segment is anticipated to hold a considerable share of the market, owing to the dispersing into the air and spreading up to one meter, infecting people nearby who breathe these droplets in. The virus also spread by hands contaminated with influenza viruses. 

The Hospitals Sub-Segment is Anticipated to Hold a Considerable Share of the Global Infectious Disease Therapeutics Market

Among the end-users, the hospitals sub-segment is projected to hold a considerable share of the global infectious disease therapeutics market. The segmental growth is attributed to the growing number of emergency hospital visits, offering reimbursement policies and facilities through insurance companies, providing prominent opportunities for the growth of this segment. These facilities prevent patients from traveling to multiple centers, enhancing the hospital sector's offerings. According to the Centers for Disease Control and Prevention (CDC), 9 million diseases, 4 million medical visits, 10,000 hospitalizations, and 5,000 fatalities were noted during the 2021–2022 influenza season.

Regional Outlook

The global infectious disease therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the increasing awareness about infectious diseases and treatments, growing FDA approvals, and driving the infectious disease therapeutics market in North America. 

Global Infectious Disease Therapeutics Market Growth, by Region 2023-2030 

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Infectious Disease Therapeutics Market

Among all regions, the Asia-Pacific region is expected to grow at the fastest CAGR over the forecast period. The growth of the market is attributed to the rising prevalence of TB, HIV, malaria, and other infections, and growing numbers of clinical trials for developing new treatment drugs. According to the WHO, in the Southeast Asian region, an estimated 3.9 million people were living with HIV in 2022, of which 81.0% knew their status, 65.0% were receiving treatment and 61.0% had suppressed viral loads. An estimated 2.6 million people were receiving antiretroviral therapy in 2022. There were 85,000 fatalities attributed to HIV-related causes in 2022, a decrease of 63.4% from 2010.  

Further, in the Western Pacific region, an estimated 2.2 million people were living with HIV in 2022, of which 81.0% knew their status, 73.0% were receiving treatment and 70.0% had suppressed viral loads. An estimated 1.6 million people were receiving antiretroviral therapy in 2022. 51,000 mortalities were attributed to HIV-related causes in 2022, a decrease of 24.7% from 2010 but an increase of 3.5% compared to 2021. Furthermore, growing the focus of governments of various countries on the prevention of infections and rising funds to surge the adoption of treatments for infectious diseases are projected to propel the market. In July 2021, China pledged funds to build new institutions and infrastructure to fight infectious diseases and improve healthcare. The central authorities supply subsidies of up to 300 million yuan ($46.32 million) for every prevention base. It can even present as many as 500 million yuan to assist native governments in arranging completely new regional medical centers. 

Market Players Outlook

The major companies serving the infectious disease therapeutics market include Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical (Johnson & Johnson), Sanofi SA, Teva Pharmaceuticals USA, Inc and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2023, Biogenysis, Inc., a wholly owned subsidiary of Enzolytics, Inc., a drug development biotech company, continued its partnership with Khalpey AI Lab and Contenta, Ltd., Estonia. Biogenysis, a partnership with Khalpey AI Lab and Contenta, Ltd. accelerated the company's objective to use AI to develop infectious disease therapeutics for improving health care around the globe. 

The Report Covers

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global infectious disease therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.